Olmesartan in Management of Proteinuria

Journal Title: Journal of Clinical and Diagnostic Research - Year 2018, Vol 12, Issue 2

Abstract

ABSTRACT Proteinuria is a marker and predictor of cardiovascular morbidity and mortality. Blockade of angiotensin receptor might result in reduction in proteinuria. Olmesartan, an Angiotensin Receptor Blocker (ARB) which is approved for the treatment of hypertension is believed to produce antiproteinuric effects through different mechanisms. The objective of this review is to assess the cause, duration and degree of proteinuria and understand the current place of olmesartan in management of proteinuria associated with Cardiovascular Disease(CVD) and hypertension. We performed a comprehensive search of MEDLINE, PubMed and Google Scholar databases for articles related to Olmesartan and proteinuria (till June 2017). Angiotensin-II induces transforming growth factor-β upregulation and increase transcapillary pressure. AT-I receptor blocked by olmesartan result in reduction in proteinuria. Olmesartan significantly reduces Blood Pressure (BP) and delays the onset of Chronic Kidney Disease (CKD), it also delayed the risk of onset of microalbuminuria. Olmesartan have nephroprotective, antioxidant, antifibrotic activities and proteinuria reducing effects which can be beneficial in patients with hypertension. Olmesartanis believed to produce antiproteinuric effects through different mechanisms. It is indicated for treatment of hypertension to reduce the risk of fatal and non fatal CV events which may or may not be associated with proteinuria.

Authors and Affiliations

Satyanarayan Routray, VN Shah, Abhay Sahoo, Priti Sanghavi, Amit Omprakash Gupta, Onkar C Swami

Keywords

Related Articles

Bilateral Psammomatoid Ossifying Fibroma of Maxilla

ABSTRACT Ossifying-Fibroma (OF) is a benign neoplasm histopathologically composed of fibrocellularstroma and variable amount of mineralized material. Generally, these tumours in jaw bones are found as solitary lesions. O...

Haemostasis with the FISH Vascular Closure Device after 6 French Transfemoral Accesses in Interventional Radiology: Clinical Results

Introduction: Endovascular procedures have increased for different indications over the recent years. To achieve a safe haemostasis after arterial puncture and for more comfort for the patients different vascular closure...

Sinonasal Neuroendocrine Carcinoma in a Young Female – A Case Report

Sinonasal Neuroendocrine Carcinoma (SNEC) is a very rare malignancy which is difficult to differentiate from other nasopharyngeal malignancies due to similar morphological characteristics and small biopsy specimen. We re...

Giving Birth After Fertility Sparing Treatment for a Yolk Sac Tumour: Case Report

Yolk Sac Tumours (YSTs) of the ovary, also called Endodermal Sinus Tumours (ESTs), are the second most common Malignant Ovarian Germ Cell Tumours (MOGCTs), after dysgerminomas. YSTs occur primarily in children and young...

Purple Urine Bag Syndrome: Series of Nine Cases and Review of Literature

ABSTRACT Purple coloured urine occurs in the patients, mainly elderly who are on urinary catheters for a long-time and develop Purple Urine Bag Syndrome (PUBS), wherein the urinary bag and the tubing turn in to purple co...

Download PDF file
  • EP ID EP519622
  • DOI 10.7860/JCDR/2018/32522.11199
  • Views 35
  • Downloads 0

How To Cite

Satyanarayan Routray, VN Shah, Abhay Sahoo, Priti Sanghavi, Amit Omprakash Gupta, Onkar C Swami (2018). Olmesartan in Management of Proteinuria. Journal of Clinical and Diagnostic Research, 12(2), 1-5. https://europub.co.uk/articles/-A-519622